Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20450604 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL1676774 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL12674184 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL20450548 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL25445243 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL20450549 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL24817622 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL17747011 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL16538711 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL20450601 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250163120-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-05-22 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| EP-4076492-A1 | PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-11358994-B2 | Fatty acid modified human epidermal growth factor | SAINT LOUIS UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200190157-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | SAINT LOUIS UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163120-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | IAPP, INSR, INSRR | KMT2A 278/4885POLB 2178/4885NOD1 2397/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | KMT2A 2065/4885POLB 3844/4885NOD1 887/4885 |
| US-20200190157-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | FABP2, FGFR2, FGF2 | KMT2A 3499/4885POLB 3479/4885NOD1 4150/4885 |
| US-11358994-B2 | Fatty acid modified human epidermal growth factor | FABP2, EGFR, HGF | KMT2A 3837/4885POLB 1942/4885NOD1 4643/4885 |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | KMT2A 1269/4885POLB 4210/4885NOD1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.